Turnover—
EBIT margin—
Net result€-202k-158.9%
Working capital€991k+21.1%
Conclusion
the dossier summarised in one paragraphThe computed 12-month bankruptcy probability of ImmuneSpec is 0.9% (low). The 2025 annual accounts show equity of €2.64M and a net result of €-202k. The company has been active since 2023 and the Belgian State Gazette contains no insolvency or warning signals.
Based on the State Gazette, CBE and 2 annual accounts.
Financials
FY 2025
€2.64M
equity
Turnover—
Net result€-202kHealth73/100 · Healthy
See full annual accounts
People & board
11 mandates
6
active directors
Kurt BoonenDirectorClean Vision Invest BVDirectorThibault JonckheereDirector+8 in history
All directors & mandates Publicationslatest 06-05-2026
17
publications in the State GazetteKurt Boonen resigns as directorAll publications & acts Network & structure
6
connected companiesSee network & structure
Connections
6 connected companiesParent · 5 subsidiaries · 1 location
Control→
Trust signals
3 signalsMore than 3 years active
Founded in 2023 — past the statistically most fragile first 3 years.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad.
Administratively compliant
No FOD Economie strikeouts (UBO, accounts, address, activity).
Administrative Flags
0 events
No administrative flags
Bankruptcy probability (12 mo)
Checked model v1 · free for everyone0.9%
Low
0%0,5%1,5%4%10%≥25%
Young company
+Lower-failure-rate sector
−Annual accounts: healthy financial profile
−
Statistical estimate based on public sources — not credit advice nor a finding of fact. How do we compute this?
Company registry (CBE)
Crossroads BankActivities
Speur- en ontwikkelingswerk op biotechnologisch gebied72101Speur- en ontwikkelingswerk op biotechnologisch gebied72110
Primary activity highlighted.
Names & trade names
| Legal nameNL | ImmuneSpec |
Registered office
Galileilaan 18 bus 6
2845 Niel, Belgium
Official data from the Crossroads Bank for Enterprises (CBE). Available for every registered company.